Introduction
Lentiviruses appear to escape from the host immune response by antigenic variation (McKnight & Clapham, 1995) , which is a major obstacle to vaccine development. Equine infectious anaemia virus (EIAV) is a lentivirus (Gonda et al., 1978) that causes life-long persistent infection and induces clinical disease characterized by periodic febrile episodes and plasma viremia (Cheevers & McGuire, 1985) . Each episode of viremia and fever is associated with the emergence of a novel Author for correspondence : Kazuyoshi Ikuta.
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The nucleotide sequence data reported in this paper will appear in the DDBJ, EMBL and GenBank nucleotide sequence databases with the following accession numbers : D87640 to D87656 and D87719 to D87733. and 12 nucleotides) located just before the insertion site were used for the duplications. Furthermore, amino acid substitutions in the env PND and hypervariable region were also observed in all five viruses. These mutations may contribute to the generation of serial variants. Consequently, the full-length gp90 sequences showed close relationships between V70, F2V and F4V, and between F1V, F3V and F5V. In addition to the two domains (PND and hypervariable region), a comparison of these viruses with the reported env gp90 sequences revealed four additional variable domains, although these four domains were highly conserved among the five variants.
antigenic variant of virus (Kono et al., 1973 ; Montelaro et al., 1984 ; Salinovich et al., 1986) . This virus is distinct from other lentiviruses such as visna virus or human immunodeficiency virus type 1 (HIV-1) which cause slow progressive courses of disease Sellon et al., 1994) . Thus, EIAV may provide an ideal dynamic system for investigating mechanisms of lentivirus persistence and pathogenesis. The antigenic variation leading to persistence of EIAV has been clearly documented by virus neutralization assays. These assays revealed that serum recovered from an experimentally infected horse effectively neutralized virus isolates recovered during earlier febrile episodes, but not those from subsequent febrile episodes (Kono et al., 1973 ; Montelaro et al., 1984 ; Salinovich et al., 1986) . Tryptic peptide and glycopeptide maps or oligonucleotide fingerprinting revealed alterations in the amino acid sequence and glycosylation pattern of Env protein (Nishimura & Nakajima, 1984 ; Payne et al., 1984 Salinovich et al., 1986) . In contrast, no variation was observed in the viral core proteins (Salinovich et al., 1986) . Rapid epitope alterations in Env glycoproteins have been documented using monoclonal antibodies against the virion surface glycoproteins (Hussain et al., 1987) . Alterations in the viral envelope may enable the new antigenic strain to escape from neutralizing antibodies, resulting in a new episode of viral replication and clinical disease .
The Env proteins of EIAV comprise the surface glycoprotein (gp90) and the transmembrane glycoprotein (gp45) (Rushlow et al., 1986) . It has been proposed that the gp90 region is divided into a variable and two (the first and second) conserved regions (Payne et al., a, 1989 . The variable region is located between the two conserved regions, and a hypervariable region was also identified in the variable region . Monoclonal antibodies that react with variable epitopes on gp90 effectively neutralize the virus, whereas non-neutralizing antibodies react primarily with conserved epitopes of gp90 and gp45 (Hussain et al., 1987 ; Payne et al., 1989) . The extracellular domain of gp45 was considered unlikely to determine neutralization sensitivity (Cook et al., 1995) . Studies using monoclonal antibodies identified three linear neutralizing epitopes on gp90 (Hussain et al., 1987 ; Ball et al., 1992) . Two of these epitopes map to amino acid residues 191 to 200 and 201 to 209, which are in the region thought to be analogous to the principal neutralizing domain (PND) in the surface unit of glycoprotein gp120 of HIV-1 V3 as it has the potential to form a loop configuration stabilized by disulfide bonds (Ball et al., 1992 ; Cook et al., 1995) . The third linear neutralizing epitope maps to amino acid residues 270 to 280 and is distinct from the potential loop structure of the PND (Ball et al., 1992 ; Cook et al., 1995) . Thus, EIAV gp90 may contain at least three separate domains (PND, hypervariable region and the region between) capable of inducing neutralizing antibodies. Therefore, the generation of EIAV escape variants should correlate with gene mutations, predominantly at the putative PND region, as they do in the HIV-1 V3 domain (McKnight & Clapham, 1995) . However, sequencing of the complete env genes of four serologically distinct EIAV variants recovered from the Malmquist-straininfected horse during periodical clinical episodes showed almost no mutations at the three epitopes mentioned above . Nine amino acid substitutions in the gp90 region enhanced the sensitivity of an EIAV variant derived from the Malmquist strain to neutralizing antibodies (Cook et al., 1995) . Again, only one of the nine amino acids was located in the PND region. Recently, it was shown that a high proportion of mutations were localized to the PND and the hypervariable region in EIAV-inoculated pony-derived samples, although there were no data on the sensitivity of the variants to neutralizing antibodies (Lichtenstein et al., 1996) . Thus, a relationship between the antigenic variations and genomic mutations at the PND has not yet been established.
Most virulent strains of EIAV cannot be propagated in tissue culture cell lines, but only in primary horse macrophage cultures . Unfortunately, primary horse macrophage cultures are difficult to maintain and are relatively short-lived (Kobayashi & Kono, 1967) . The Malmquist strain, generally used as a virulent EIAV, was derived from the wildtype Wyoming strain (Malmquist et al., 1973) . Although the long-term replication of the virus in equine dermal fibroblast cell lines attenuates the in vivo pathogenic potential of the prototype Wyoming strain of EIAV (Malmquist et al., 1973) , pathogenic EIAV is recovered by passage in vivo from cell culture-adapted EIAV variants without a concomitant loss of the ability to replicate in these fibroblasts (Orrego et al., 1982) . Amino acid sequence comparisons between EIAVs adapted and non-adapted to cell culture revealed a significant difference in the Env gp90 of 11n0 %, but that of Gag and Pol is only less than 1 % (Perry et al., 1992) .
In this report, we determined the env sequences of five viruses recovered during periodic febrile episodes from a horse experimentally infected with a virulent strain, V70, which was cloned using primary horse macrophages directly from a diseased horse (Kono & Kobayashi, 1970 ; Kono et al., 1973) . Cross-neutralization tests showed that all these viruses, as well as V70, were antigenically distinct. The results revealed that major mutations occurred in the PND and partly in the hypervariable region. We also revealed, by comparison with known gp90 sequences derived from EIAV, that there are at least six variable domains (V1 to V6) in the gp90 of EIAV showing various biological phenotypes. All of the domains, including the V3 (PND) and V5 domains (hypervariable region), seemed to be mainly involved in differences among virus strains and only partly in the in vitro passage history of the virus.
Methods
Virus, cell cultures and virus infection. The virulent strain of EIAV, V70, has been described in detail elsewhere (Kono & Kobayashi, 1970) . Briefly, V70 was isolated by three repeated limiting dilutions of EIAV from a diseased horse. For the limiting dilution and viral propagation, we used primary horse macrophages. Horse No. 493, inoculated with this V70, exhibited typical clinical signs of disease with periodical relapse of fever (Fig. 1 a) , as reported (Kono et al., 1973) . Variants (F1V, F2V, F3V, F4V and F5V) were obtained from the serum of this horse at each of the five febrile episodes by three repeated limiting dilutions under the same conditions and subjected to DNA sequencing. In addition, horses No. 571 to 575 were inoculated with F1V to F5V, respectively. The viruses in the sera at each febrile episode were propagated in primary horse macrophages. These viruses were directly subjected to PCR amplification without limiting dilution.
Equine adherent macrophage cultures were established by separating horse peripheral blood mononuclear cells and plating them with complete medium (MEM supplemented with 10 % homologous horse serum and 40 % bovine serum) (Kobayashi & Kono, 1967) . After a 24 h incubation, non-adherent cells were removed from the cultures by washing them once with serum-free MEM. The adherent macrophages were then infected with each virus and incubated at 37 mC until cytopathic effects appeared on day four or five post-infection. Virus neutralization test. The sera obtained from infected horse No. 493 at each febrile episode were heat-inactivated at 56 mC for 30 min. Equal volumes of serial twofold dilutions of the serum were mixed with 200 TCID &! \ml of the above five viruses as well as the original V70, then incubated for 1 h at 37 mC. The horse macrophage cultures in four tubes were inoculated with each virus mixture and incubated at 37 mC. Infectivity was titrated by the appearance of cytopathic effects in the cultures 10 days after inoculation. The neutralizing antibody titre was expressed as the reciprocal of the serum dilution which inhibited the specific cytopathic effects.
Preparation of total cellular DNAs from EIAV-infected macrophage cultures.
The infected macrophages showing cytopathic effects were removed using a rubber policeman and washed twice with PBS. The cells were resuspended and lysed in 0n5 % SDS, 10 mM TrisHCl (pH 7n8) and 5 mM EDTA. The lysate was digested with proteinase K (0n04 mg\ml) at 37 mC for 24 h. The DNAs in the lysates were extracted with phenol\chloroform-isoamyl alcohol (24 : 1) and precipitated with ethanol. The cellular DNAs were then dissolved in TE buffer and adjusted to 1 µg\µl.
Amplification and cloning of the env region. The primer sequences used for PCR amplification in this experiment are summarized in Table 1 . Their nucleotide maps were derived from the sequence of the proviral clone CL.22. PCR amplification of several fragments of EIAV DNA in total cellular DNAs (1n0 µg), as shown in Fig. 2 , was carried out using a DNA thermal cycler PJ2000 (Perkin Elmer).
The fragment (nucleotides 4696 to 7468) encompassing the end of pol, full-length env gp90 and half of gp45 was amplified with the primer pair ENV-D5 and ENV-A5 using an XL PCR kit (Perkin Elmer). The incubation profile was 1 cycle of 1 min at 94 mC and 30 cycles each of 1 min at 94 mC, 4 min at 64 mC and 10 min at 72 mC. This amplified fragment was used as a template to generate a smaller fragment (nucleotides 5591 to 6687) with the primer pair ENV-D1 and ENV-A1 using Taq polymerase (Perkin Elmer) according to the following incubation profile : 1 cycle of 1 min at 94 mC and 35 cycles each of 1 min at 94 mC, 1 min at 60 mC and 3 min at 72 mC. In addition, the fragment (nucleotides 5801 to 6306) in total cellular DNAs was also amplified with the primer pair EPND-D2 and EHPR-A1. The incubation profile was 1 cycle of 1 min at 94 mC and 35 cycles each of 1 min at 94 mC, 1 min at 56 mC and 1n5 min at 72 mC. After washing with chloroform-isoamyl alcohol (24 : 1), the EIAV DNAs in these fragments at nucleotides 5591 to 6687 and 5801 to 6306 were directly cloned into the pCR vector (Invitrogen). The primer pair EPND-D2 and EPND-A1 was also used to amplify the PND region (nucleotides 5801 to 5913). The incubation profile was 1 cycle of 1 min at 94 mC and 35 cycles each of 45 s at 94 mC, 1 min at 57 mC and 1 min at 72 mC.
Nucleotide sequencing. The first PCR-amplified fragment (nucleotides 4696 to 7468) was purified by gel elution from 0n8 % lowmelting agarose (Wako, Japan). The region (nucleotides 5277 to 5590) was directly sequenced using [α-$#P]ATP-labelled synthetic primers according to the protocol supplied with the CircumVent Thermal Cycle DNA sequencing kit (New England Biolabs), as described by Kishi et al. (1995) .
On the other hand, the DNA clones containing EIAV DNA (nucleotides 5591 to 6687 and 5801 to 6306) in plasmids were automatically extracted using the isolation system PI-100 (KURABO, Japan) and used for sequencing reactions in either Taq Clinical disease characterized by periodic febrile episodes of fever appeared after inoculation until the horse was killed on day 163 post-inoculation. Virus was isolated at each peak of body temperature on days 20, 44, 62, 83 and 155 post-inoculation (a). The isolates were named F1V, F2V, F3V, F4V and F5V, respectively. The same sera as used for virus isolation were used for virus neutralization tests to each virus isolate as well as V70 (b). The neutralizing activities were expressed as the reciprocal of the highest serum dilution (log 2 ) inhibiting EIAV-specific cytopathic effects.
forward and reverse primers (Applied Biosystems). Sequences were resolved with an ABI 373 sequencer (Applied Biosystems).
The env gp90 sequences derived from EIAV with various biological phenotypes. The following reported sequences were used : CL.22 (GenBank accession number M87581) (Perry et al., 1992) , CL.1369 (M16575) (Kawakami et al., 1987) and MA-1 (M58039) derived from cell culture-adapted EIAVs ; pCD (M87580) (Perry et al., 1992) and Th-1 (M62655 to 62680) derived from cell culture non-adapted, virulent EIAV ; and pSPEIAV44 (U01867) (Payne et al., 1994) and WSU5 (X16988) (McGuire et al., 1990) derived from cell culture-adapted EIAVs, the pathogenicity of which was regained by passages in vivo. Plasmid pCD was derived from the wild-type Wyoming strain, whereas CL.22, CL.1369, pSPEIAV44 and WSU5 were derived from the Malmquist strain. Th-1 was isolated during a febrile episode of a horse experimentally infected with the Massachusetts field isolate of EIAV (Carpenter et al., 1987 ; Carpenter & Chesebro, 1989) . MA-1 is a variant of Th-1 isolated by in vitro replication in equine dermal cells, which resulted in a loss of tropism for in vitro replication in primary horse macrophages, and also a loss of virulence (Carpenter et al., 1987) .
Nucleotide sequence analysis. The nucleotide and amino acid sequences were analysed by GENETYX-MAC (Software Development, Japan).
Results

Antigenic distinction of the viruses serially isolated at each febrile episode
Horse No. 493 inoculated with a virulent strain of EIAV (V70) exhibited typical clinical signs of disease with periodical relapse of fever (Fig. 1 a) . By means of culturing, followed by cloning in primary horse macrophages, a total of five variants (F1V, F2V, F3V, F4V and F5V) was obtained from this horse sera during the febrile episodes. Virus neutralization tests using the same sera as for virus isolation revealed clear antigenic distinction among V70 and the above five isolates (Fig. 1 b) . The serum obtained at F1V isolation did not neutralize V70 or any of the five isolates. However, the serum obtained at F2V isolation exhibited moderate neutralizing activity against F1V
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In vivo generation of EIAV variants
In vivo generation of EIAV variants Fig. 2 . Sequencing strategy after PCR amplification of V70 and V70-derived variants at the env region. The numbers for EIAV env sequences described here correspond to the reported EIAV numbering scheme (CL.22 ; GenBank accession number M87581). The first PCR was performed to amplify a fragment of 2772 bp in total cellular DNAs using the primers ENV-D5 and ENV-A5. The second PCR amplified fragments using primers ENV-D1 and ENV-A1. The nucleotide sequences at the env fulllength gp90 and fusion domain (FD) of gp45 were determined by either directly sequencing the PCR products at nucleotides 5277 to 5590, or after cloning the products into a pCR cloning vector at nucleotides 5591 to 6687. In addition, the same total cellular DNAs were subjected to PCR amplification of the fragment containing PND and hypervariable region using primers EPND-D2 and EHPR-A1. The nucleotide sequences were determined after cloning the products into a pCR cloning vector at nucleotides 5801 to 6306. The regions for the conserved and variable domains or for the PND and hypervariable domains are shown according to the literature (Ball et al., 1992 ; and V70, but no neutralizing activity against F2V to F5V. In addition, the serum at F3V isolation neutralized F1V, F2V and V70, but not F3V to F5V. The serum at F4V isolation neutralized F1V to F3V and V70, but not F4V and F5V. The serum at F5V isolation neutralized F1V to F4V and V70, but not F5V. Thus, the infected horse induced neutralizing antibodies to viruses recovered during earlier febrile episodes, but not those from subsequent febrile episodes. Next, we determined whether or not there were differences at the nucleotide and amino acid sequence levels among these variants and parental V70.
Accumulation of mutations in the variable region of gp90 in five variants obtained during clinical episodes in a horse infected with V70
Because of the existence of an unstable promoter sequence in the env start region (Cunningham et al., 1993) , the region at nucleotides 5277 to 5590 was directly sequenced using DNA purified from a gel containing the first PCR product (Fig. 2) . The region at nucleotides 5591 to 6687 in gp90 of each variant and of V70 were PCR-amplified and cloned, as shown in Fig. 2 . First, two DNA clones were randomly selected for sequence determination. The full-length nucleotide sequences of gp90 and gp45 start region from each virus are shown in Fig. 3 . Their deduced amino acid sequences are shown in Fig. 4 . The sequences revealed mutations in a limited number of nucleotide positions of gp90, i.e., insertions and duplications at the PND only in three variants (F1V, F3V and F5V) and substitutions at the PND and hypervariable region in all five variants, compared with the sequences of the original V70.
There were also several substitutions throughout the sequences examined. In the first conserved region of gp90, identified by , all viruses examined (V70 and five variants) had the same sequence, except for one base substitution of G to A at nucleotide 422 in two clones of F3V. There were slightly more base substitutions in the second conserved region and the start region of gp45. One G to A substitution at nucleotides 689 and 1291 was identified in clones of F1V and F5V, respectively. Other substitutions, including silent mutations in the full-length gp90 and in the fusion domain of gp45 seemed less significant to the differentiation among the viruses, but significant for differentiation among several DNA clones derived from an individual virus. In addition, a three-base deletion at the end of the variable region was found exclusively in clones of F1V, F4V and F5V. Thus, isolates from the V70-inoculated horse obtained during febrile episodes mutated in the restricted regions, especially in the PND and hypervariable region. The sequencing of additional two or three DNA clones only at the PND and hypervariable region confirmed the same variations in all five variants as well as V70 (not shown). In addition, the mutations at the PND and hypervariable region were confirmed by independently amplified PCR products with primer pairs EPND-D2 and EHPR-A1 at nucleotides 5801 to 6306 (Fig. 2) . The sequencing of the DNA clones obtained from the PCR products also showed the same variations in these regions (Fig. 3) . 
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In vivo generation of EIAV variants Fig. 3 . Nucleotide sequence of the full-length gp90 and gp45 start region in V70 and V70-derived variants. PCR amplification using total cellular DNAs from the cells infected with V70 or V70-derived variants proceeded as shown in Fig. 2 . Numbering begins with the initiator codon (ATG) of V70. The nucleotides 1 to 307 were determined by direct sequencing of the first PCR products. The other portion, nucleotides 308 to 1398, was sequenced after cloning the second PCR products, using primers ENV-D1 and ENV-A1, into the pCR cloning vector. For the latter, the results of two randomly selected DNA clones from V70 (V70-1 and -3), F1V (F1V-1 and -2), F2V (F2V-1 and -2), F3V (F3V-1 and -2), F4V (F4V-2 and -8) and F5V (F5V-1 and -2) are shown here. In addition, nucleotides 518 to 1014 were sequenced after cloning the independent PCR products from the same total cellular DNAs using primers EPND-D2 and EHPR-A1. Next, we examined the pathogenicity of EIAVs with mutations at the PND. Another horse (No. 571) was inoculated with the F1V isolate obtained at the first episode of V70-inoculated horse No. 493. This horse also showed typical clinical signs of disease. The viruses in the sera obtained from horse No. 571 at five sequential episodes were propagated in primary horse macrophages, without limiting dilutions. These viruses were designated 11V, 18V, 37V, 70V and 77V (Fig.  5 i) . The cellular DNAs were extracted directly from infected cells, then subjected to amplification of the PND region using primers EPND-D2 and EPND-A1. As shown in Fig. 5 (ii), the predominant virus populations in 11V, 18V and 37V showed a PND structure similar to F1V, F3V or F5V, whereas those in 70V and 77V showed a PND structure similar to F2V or F4V. Similar results were also obtained in EIAV isolates derived from horses No. 572 to 575 inoculated with F2V to F5V, respectively (not shown). Thus, the insertions also occurred during febrile episodes in F1V-to F5V-infected horses.
Mutation mechanisms for the in vivo generation of five variants
Since the four or five DNA clones had similar sequences (Figs 3 and 4) , we examined the regular mutation mechanisms in parts of the PND and hypervariable region that generated escape mutants by using representative sequences of each variant (Fig. 6 ). To identify insertions and duplications in the PND, the sequence located just before the insertion region was used. This sequence was separated into SU1 (TGTCAAAAA), SU2 (GTTAAT), SU3 (GTTAGT) and SU4 (GAGAGTA-CGGAA) (Fig. 6 a) . SU3 differed from SU2 by a single base substitution from A to G. In the sequence before the insertion region in F1V, F2V and F5V, SU2 was tandemly duplicated in place of SU3. The insertion region consisted of SU1, SU2 and SU4 in F1V, and SU1, SU2, SU2 and SU4 in F3V. In the insertion region of F5V, TATTTA and GTTAAA were inserted in the 5h region before SU2 and SU4. The origin of the sequence TATTTA is unknown, whereas the sequence GTTAAA seems to be a substituted form of SU2. Thus, F1V, F3V and F5V were distinct from the original V70 even at the amino acid level, whereas F4V was the same as V70 in this region (Fig. 6 b) . However, an additional mutation was also identified in the PND as a Ser to Asn substitution in F1V, F2V and F5V. Therefore, F2V was distinct from V70 or other variants. To identify the difference between F4V and V70 or other variants, the hypervariable region was also examined (Fig. 6) . The sequences were identical between V70 and F2V (Fig. 6 a) three substitutions at both the nucleotide (Fig. 6 a) and amino acid (Fig. 6 b) levels were detected in F4V, which may be effective in differentiating V70 from other variants. Thus, V70, F1V, F3V and F5V differed at the insertion sites in the PND. F2V differed from V70 and other variants by a substitution in the PND, while F4V differed from V70 and others by a substitution in the hypervariable region. The potential N-linked glycosylation sites in V70 and the five V70-derived variants were significantly altered by these insertions, duplications and substitutions in the PND and hypervariable region. One Asn glycosylation motif was identified in PND of V70, F2V and F4V, whereas there were two sites in three other variants at the same and\or different site(s) (Fig. 6 b) . In addition, Asn in the hypervariable region of F4V and F5V became a potential N-linked glycosylation site by substitution from Lys to Thr as shown in Fig. 6 (b) .
Comparison of V70 and V70-derived variants with the reported EIAV env sequence
The known env gp90 sequences were compared with those of V70 as well as the five variants obtained from the V70-inoculated horse during febrile episodes (Fig. 7) . We used the reported sequences CL.22, CL.1369, MA-1, pCD, Th-1, pSPEIAV44 and WSU5.
Computer analyses of the full-length gp90 in these 13 EIAVs revealed the presence of at least six variable domains (tentatively named V1 to V6) within the coding sequence (Fig.  7 a) . These results differ slightly from those reported by . The V1 domain was located within the region which was proposed to be conserved, although the V2 to V6 domains were within the variable region. These six domains were significantly different among our EIAV, the Wyoming strain and the Massachusetts strain.
As shown in Fig. 7 (b) , domain V3 in the PND and V5 in the hypervariable region caused the major differences among V70 and the five variants. The sequences of pCD were similar, at least in part, to the insertion forms of V70 such as F1V, F3V and F5V in the PND and the substitution forms of V70 such as F3V to F5V in the hypervariable region. In contrast, the sequences in the V3 and V5 domains derived from other horse cell culture-adapted strains were all markedly different from those of V70, the five V70-derived variants and pCD. However, a comparison with virulent in vivo-derived Th-1 and its cell culture-adapted MA-1 revealed that the V3 and V5 domains of both sequences were not significantly different and were quite similar to several other cell culture-adapted viruses, although only one amino acid (Asn) in Th-1 V5 domain, in place of Asp in MA-1 V5 domain, was the same as that in V70 and V70-derived variants. The sequences in the V3 and V5 domains of cell culture-adapted EIAVs that regained pathogenicity after passages in vivo were not significantly different from the original culture-adapted viruses.
The sequences of the V1 and V2 domains of pCD and Th-1 were rather similar to the cell culture-adapted strains, including EIAVs that regained pathogenicity, but differed from V70 and its variants (Fig. 7 b) . Again, one amino acid (Ile) in Th-1 V2 domain, in place of Met in the MA-1 V2 domain, was the same as that of V70 and V70-derived variants. Two amino acids were inserted into the V1 domain in several cell cultureadapted strains, including those which regained pathogenicity, although the V1 sequences of pCD and Th-1 also have a similar insertion.
In domains V4 and V6, the sequence of pCD was closely related to those of V70 or its derived variants, whereas that of Th-1 was closely related to those of cell culture-adapted strains including EIAVs that regained pathogenicity (Fig. 7 b) .
In addition, there was a marked difference in two sites (at amino acid residues 219 and 235). Leu#"* in the sequences from EIAVs not adapted to fibroblastic cell cultures, such as V70, V70-derived variants, pCD and Th-1 was changed to Phe#"* in the sequences from adapted EIAVs, such as CL.22, pSPEIAV44, CL.1369, WSU5 and MA-1. The Ser#$& in the sequences from V70, F2V-F5V and pCD was changed to Asn#$& in the sequence from F1V, to Thr#$& in the sequences from CL.22, pSPEIAV44, CL.1369 and WSU5, and to Arg#$& in the sequences from Th-1 and MA-1.
Essentially similar results were also obtained from a phylogenetic tree constructed using full-length gp90 (not shown). The V70 and five V70-derived variants greatly differed from three EIAVs adapted to horse fibroblastic cells (CL.1369, CL.22 and MA-1). The sequences from two viruses (pSPEIAV44 and WSU5) were rather close to those from the adapted viruses. On the other hand, the sequence of pCD was located in the group of V70 and V70-derived variants. F1V, F3V and F5V were closely related, and these viruses differed from V70, which was closely related to F2V and F4V. In vivo generation of EIAV variants In vivo generation of EIAV variants (a) (b) Fig. 7 . Consensus amino acid sequence and sequence divergence in the gp90 region between V70 or V70-derived variants and those of known viruses. The env gp90 sequences were derived from V70-1 and five V70-derived variants (F1V-1, F2V-1, F3V-1, F4V-2 and FQD5V-1), pCD, pSPEIAV44, WSU5, CL.22, CL.1369, MA-1 and Th-1. Their deduced amino acid sequences were analysed using GENETYX-MAC (a). Amino acid residues that were conserved in the majority of their sequences are shown as consensus amino acid residues. Vertical columns indicate the number of divergent amino acid residues. Six variable domains (named V1 to V6) identified in this analysis are underlined in (a) and their amino acid sequences are shown in (b). Similarly, two hypervariable amino acid residues are marked by (*) in (a) and their amino acid sequences are also shown in QD(b). Since part of the gp90 sequence of Th-1 was not available , (a) was constructed with some of the information of this virus sequence.
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Discussion
Five variants were isolated from periodic febrile episodes of horse No. 493 experimentally inoculated with virulent EIAV (V70) propagated in primary horse macrophages (Fig. 1 a) . Antigenic distinction of the five variants, as well as V70, was revealed by neutralization tests using the same sera as for individual virus isolates (Fig. 1 b) , as described previously (Kono et al., 1973) . The five variants were distinguishable by insertions and duplications at the PND and substitutions at both the PND and the hypervariable region (Fig. 6) . Another horse, No. 571, inoculated with F1V with the insertion at the PND also had febrile episodes. Agarose gel electrophoresis of PCR products from the PND revealed similar mutations in variants which were propagated in primary horse macrophages and were not cloned by limiting dilution at febrile episodes (Fig. 5 ). In addition, at least six variable domains (V1 to V6) as well as two hypervariable amino acid residues were identified in the sequence of the full-length gp90 region by comparison with the known gp90 sequences from other viruses with various phenotypes (Fig. 7) . The V1 proposed here is located within the region originally identified as the first conserved region, while another five domains and two hypervariable amino acid residues were located in the region identified as the variable region .
EIAV Env gp90 contains at least three neutralizing epitopes, as determined using neutralizing monoclonal antibodies (Ball et al., 1992) . These were amino acid residues 191 to 200 (named E), 201 to 209 (named D) and 270 to 280 (named C) (Fig. 7 a) . The E and D epitopes were located within the PND V3 domain. The entire sequence of epitope E, and part of that of epitope D, were undetectable in V70 because the sequences were located in the insertion sites seen in F1V, F3V and F5V. However, the sequence for epitope C, partly located in domain 4, was not altered among V70 and five V70-derived variants, although it was substituted by three amino acid residues in adapted viruses. The V5 domain identified here was located in the hypervariable region, which was identified by sequencing EIAV variants isolated from a febrile episode of another horse . The results of this study show that mutations among the five variants and V70 were concentrated in V3 and V5 (Fig. 7 b) . Together with epitope analyses, the data presented here suggest that at least domains V3 in the PND and V5 in the hypervariable region could be immunodominant and involved in generating virus variants in a horse inoculated with V70 in parallel with periodical febrile episodes in our system. The PND seems to be the major immunodominant domain, resembling the V3 domain of HIV-1 Env gp120 (McKnight & Clapham, 1995 ; Nowak et al., 1995) . The HIV-1 V3 domain is believed to be exclusively involved in the generation of escape mutants, as evidenced by in vitro neutralization assays, and V3 mutations have been found in in vivo isolates from human and chimpanzee HIV-1 carriers. However, the mutation mechanism for escape in HIV-1 is mainly amino acid substitution at the V3 domain (McKnight & Clapham, 1995) , which seems to be similar to that of the hypervariable region of EIAV, as shown in Fig. 6 . Cytotoxic T lymphocytes (CTL) may be more involved in the generation of EIAV escape variants, since the V3 domain of HIV-1 also contains epitopes for CTL as well as neutralizing antibodies (Koup et al., 1994 ; Pantaleo et al., 1994) . In addition, CTL are more effective than neutralizing antibodies in reducing virus load at the early acute phase in infected individuals (Koup et al., 1994 ; Pantaleo et al., 1994) . Therefore, the contribution of CTL to the generation of escape mutants in infected horses must be considered.
Insertion at the V3 domain in the PND was not random. Combinations of small units (SU1 to SU4 motifs) located just before the insertion site were duplicated (Fig. 6) . The F1V variant, which differed greatly from the V70 inoculum, was the first to appear. The two resulting populations (V70 and F1V) were used to generate subsequent variants by minor substitutions : V70 to F2V followed by F4V, and F1V to F3V followed by F5V. Thus, this mechanism in EIAV could be a good model for generation of escape lentivirus variants, since such study on mutation mechanism has not been done for other lentiviruses, e.g. HIV-1.
It is possible that the mutations found in this study were PCR artefacts. However, misreading or template switching by the Taq polymerase would be a random event. Therefore, it would not have caused mutations at a limited number of nucleotide positions in all DNA clones from one virus sample, as seen in Fig. 3 . In fact, the sequencing of independently amplified PCR products confirmed the variations in the PND and hypervariable region (Fig. 3) .
In contrast to our findings, other investigators have obtained different results using similar infection systems, but different sources of virulent EIAV strain as inoculum . However, the same group has recently shown substitutions at the PND and the hypervariable region (Lichtenstein et al., 1996) . We used V70, which was directly cultured in primary horse macrophages from a diseased horse (Kono & Kobayashi, 1970) , whereas they used the Malmquist strain, which regained virulence following in vivo passage of fibroblastic cell-adapted virus (Orrego et al., 1982) . The wildtype EIAV (V70) does not replicate as markedly in horse fibroblasts (Kono & Yokomizo, 1968) . Comparison of gp90 sequences derived from the 13 viruses including our V70, V70-derived variants and the corresponding published sequences at the amino acid level revealed at least six variable domains (V1 to V6) discretely distributed throughout the gp90 sequence (Fig. 7) . The V3 and V5 domains could be involved in the antigenic variation, as evidenced by the differences between V70 and V70-derived variants. Another four domains were only partly involved in the differences among EIAV tropisms : in vivo-derived and virulent, cell culture non-adapted virus and avirulent, cell culture-adapted virus. However, the nature of EIAV virulence regained by in vivo passage of cell culture-adapted virus was not necessarily associated with these differences. In addition, two amino acids were also identified as hypervariable (Fig. 7) . The sequences were significantly different at all these domains, and so were the two amino acid residues among our viruses, the Wyoming and the Massachusetts strain derivatives (Fig. 7) . Thus, these variable regions seemed to be the main cause of the differences between the EIAV strains.
Comparisons between EIAVs adapted, or not, to cultured cells revealed some common differences in these variable regions (Fig. 7) . The sequence of pCD was similar to our V70 or V70-derived variants, at least in domains V3 to V6. Perry et al. (1992) have shown differences in the gp90 domains, including V3 to V6, by comparing the sequences derived from cell culture-adapted (CL.22) and non-adapted EIAVs (pCD). However, the sequence of non-adapted Th-1 was rather similar to those of cell culture-adapted EIAVs in these domains, including the Th-1-derived variant MA-1, although minor differences were evident in domain V5. In contrast, the V1 and V2 sequences were similar between pCD and CL.22, but quite different from our V70 and V70-derived variants (Fig. 7) . In fact, the sequence of our attenuated V26, which had gone through 50 passages of V70 in primary horse macrophages, was similar to that of cell culture-adapted EIAVs, but not to that of V70, in terms of the two amino acid insertions in the V1 domain (unpublished result). We cannot rule out the possibility that virulent and avirulent viruses differ in regions other than the V1 to V6 domains identified here. In fact, a significant divergence in the long terminal repeat has been identified between Th-1 and MA-1 . The sequences derived from the viruses (pSPEIAV44 and WSU5), the pathogenicity of which was regained by in vivo passages of cell culture-adapted avirulent virus, were not significantly different from those of the original adapted virus, indicating that these are mutations involved in virus pathogenicity in regions other than the V1 to V6 domains. Thus, it seems that mutation sites differ according to the in vitro passage history of the virus or the host cells used for propagation.
In conclusion, we reveal dynamic mutations in the env V3 PND and V5 hypervariable region, probably associated with the generation of novel escape variants in vivo. At least six domains and two hypervariable amino acid residues in the env gene are involved in different viral sources and only partly in the adaptation to horse cell culture. Quantitative PCR using our V70 virus is now in progress to determine when subsequent novel variants are generated in vivo and in vitro.
